Non-Transfusion-Dependent Thalassemia
Non-Transfusion-Dependent Thalassemia includes inherited hemoglobin disorders causing chronic anemia. Genetic variants influence disease severity and therapeutic options.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Non-Transfusion-Dependent Thalassemia in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| Liver iron concentration imaging |
|
Defined at the solid tumor level and applicable to Non-Transfusion-Dependent Thalassemia and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Non-Transfusion-Dependent Thalassemia. Select a therapy to view the specific approval and eligible tests.
Liver iron concentration imaging (based on the proton transverse relaxation rate of MRI images)